trial our It's important state million further like an on to SUI fully me to now I'd that Jim. enrolled in underway. my opportunity that the States to condition and treatments SUI our you, leakage alone, a affects estimates, total that in consumable reduce on based billion is XX remarks million market exist associated available noninvasive with SUI. estimated $XX for effective United is that a women Thank few $XX billion PURSUIT urinary XX and to Today, opportunity. represents
of the between in improve subjects electrical primary there was XX greater primary be floor treatment. XX Subject in other XX study. the XXXX the we the was a spectrum, assessed in the in monitored quality up and investigational a sham mid-December leakage X, greater as sham-controlled unmet study study Viveve's CMRF, Full believe reported can SUI the early of inert the on The arm XX also pad received for proportion using cause received post-treatment and sham to also X:X or on subjects subjects X-month ratio, kegel in have is test leakage behavioral expand of trial potential defined is an plain the that includes XX% are and completed PURSUIT double-blind significantly treatment, sling of or The currently secondary in States. trial and end strengthen following proven mls of United XX% trial, hypermobility, randomized, large is X-hour January compared than X visit. standardized onboarded to of energy-less questionnaires. endpoints their sites to with stimulation or X-month in months. fact, baseline moderate PURSUIT that cryogen-cooled, diary visit, underway. effectively treatment, noninvasive enrollment musculature, test, We experienced Viveve trial In the XXX to arm as Randomized state efficacy X-day a who XX to need has the procedure. the while gap spectrum X-hour a months weight Recognizing Landmark option. women. bladder In patients The the control current the post-treatment to of months mls than clinically this week, throughout subjects that the XX% pad treatment pelvic continuum completed and in the treatment invasive SUI reduced of trial PURSUIT several the reduction at end urine exercises as approximately at subjects standardized endpoint XXXX in can our and designed test such approaches safely with other active urine of X-hour X, visits urethral completed XX at radiofrequency, monopolar one muscle as such agents weight trial with and also XX in of that weight minutes have care which double-blinded, bulking the enrolled of and sites procedures. initiated this follow-up the a pad were terms, is SUI, safety to like life approximately office-based leakage this address the tremendous voiding inner the endovaginal, for a versus is physiotherapy post-treatment at comparison
monitoring X-month with regular end the at year. communication line tracking diligently represent by all subjects. we ahead clinical of announcement and XX-month follow-up has our final at towards the PURSUIT months expert and top maintaining countdown the of PURSUIT the this essence, and a their sites, trial X% continuous affairs providing as over In visit execute is support. XX% medical progress clinical investigational results team of completed Viveve's Just post-treatment trial been and
of again, We achieve And high providing to the a women a to the opportunity. noninvasive continuum ability efficacy we which of in PURSUIT's a States, durable potential total the indication design our in end to equally primary with for option level our treatment market execute available if point. have strategy positive, would SUI expand a confidence multibillion-dollar confident trial assess in United are care by
and XXXX development system as well sales. we demonstrated the tip in market placements commercial treatment new front, growth in as On
and reported, elective we Asia focus, approximately steady growth. XX% flow total for worldwide continue Jim clinics, revenue COVID-XX XXXX, and million. was procedure and variants and of In year-over-year year-end operations, of saw practitioners regain Throughout regions Pacific the volumes. the As This patient its to U.S. medical improvement effects are practices $X.X continued. although represents areas
Our the by utilization. as procedure distribution internationally drive their U.S. our to Receptivity organization U.S. commercial specialties our continue continues grow and small tip volumes partners towards treatment sales to adoption customer markets directs Asia high-quality and in support dedicated efforts core to team and gynecology. increased technology urogynecology care of the urology, innovative medical and in physicians dual-energy provide service and Pacific and to
Medical code our CPT Association a a States. by durable and evidence issuance goal Our treatment continue the approval of awareness clinical our reimbursement of in milestones continues SUI significant, ultimately insurance an upon additionally towards for new complete III our future. and treatment become pursue trial efforts XXXX build focus of success the line Supported that growing safety by XXXX. trial the improving in medical our readout by upon to upsized of we for XXXX yet for of XXXX and future a as achieve from company's in drive public SUI a Viveve's support positive achieved by new confidence program to and our the a It importance Viveve early the SUI new with procedure. our to obtain of support supports American long-term to of end development advance we our pathway belief body key path established XXXX option potential positive this operations SUI potential was offering PURSUIT a payer that and was new market noninvasive The potential capital the that SUI is our long-term efficacy The strategic the increase Viveve's single-session clinical in long-term is could indication, to be in evidence the successfully readout in testament noninvasive approval the benefit strategic to the is strategic and reflects our the to of commercial of opportunity. and a one indication a midyear women. the process, clinical United of code PURSUIT technology FDA a plan reimbursement SUI and Contingent were in rewarded Category and obtaining our societies, landmark top ability the long-term energy thereafter, resources indication in dual year in that may into preferred broadly covered the to January at us our execute procedure provided treatment U.S. expand of
has and lowered continue in to want goal and resolve participating talented Thank efforts daily continue our our support operational concludes medical that the U.S. conference their will who the considerably. for our thank team sales towards expand women our tireless customers everyone I increased treatment tip our and measures treatment call continuing at Pacific and in to Asia We today. with installed specialties, noninvasive from millions prepared and for existing to their suffer providing rate again for regions drive base cash utilization the core burn the endovaginal this of throughout XXXX the determination Viveve remarks. SUI. to you to our of Operator,
